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Abstract
Background: Lubricin/proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblasts and
superficial zone chondrocytes. PRG4 has a homeostatic multifaceted role in the joint. PRG4 intra-articular treatment
retards progression of cartilage degeneration in pre-clinical posttraumatic osteoarthritis models. The objective of this
study is to evaluate the binding of recombinant human PRG4 (rhPRG4) and native human PRG4 (nhPRG4) to toll-like
receptors 2 and 4 (TLR2 and TLR4) and whether this interaction underpins a PRG4 anti-inflammatory role in synovial
fluid (SF) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
Methods: rhPRG4 and nhPRG4 binding to TLR2 and TLR4 was evaluated using a direct enzyme linked immunosorbent
assay (ELISA). Association of rhPRG4 with TLR2 and TLR4 overexpressing human embryonic kidney (HEK) cells was studied
by flow cytometry. Activation of TLR2 and TLR4 on HEK cells by agonists Pam3CSK4 and lipopolysaccharide (LPS) was
studied in the absence or presence of nhPRG4 at 50, 100 and 150 μg/ml. Activation of TLR2 and TLR4 by OA SF and RA
SF and the effect of nhPRG4 SF treatment on receptor activation was assessed. PRG4 was immunoprecipitated from
pooled OA and RA SF. TLR2 and TLR4 activation by pooled OA and RA SF with or without PRG4 immunoprecipitation
was compared.
Results: rhPRG4 and nhPRG4 exhibited concentration-dependent binding to TLR2 and TLR4. rhPRG4 associated with
TLR2- and TLR4-HEK cells in a time-dependent manner. Co-incubation of nhPRG4 (50, 100 and 150 μg/ml) and Pam3CSK4
or LPS reduced TLR2 or TLR4 activation compared to Pam3CSK4 or LPS alone (p <0.05). OA SF and RA SF activated TLR2
and TLR4 and nhPRG4 treatment reduced SF-induced receptor activation (p <0.001). PRG4 depletion by
immunoprecipitation significantly increased TLR2 activation by OA SF and RA SF (p <0.001).
Conclusion: PRG4 binds to TLR2 and TLR4 and this binding mediates a novel anti-inflammatory role for PRG4.
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Background
Lubricin/proteoglycan-4 (PRG4) is a glycoprotein secreted
from synovial fibroblasts and superficial zone chondro-
cytes that has a multifaceted function including boundary
lubrication, resulting in lowering of friction between ap-
posed cartilage surfaces [1–9]. PRG4 is abundant in the
synovial fluid (SF) and its levels are reduced in SF from
patients with inflammatory arthropathies [10, 11]. The
homeostatic role of PRG4 in the joint is evidenced by the
ability of purified native protein, recombinant full-length
or truncated PRG4 to retard cartilage degeneration,
enhance cartilage repair and reduce chondrocyte apop-
tosis in preclinical surgically induced osteoarthritis (OA)
models [12–17].
Recently, we have demonstrated that recombinant hu-
man PRG4 (rhPRG4) binds to recombinant human CD44
receptor in a concentration-dependent manner [18]. The
interaction of rhPRG4 and CD44 on the surface of
rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)
results in inhibition of nuclear factor kappa B (NFκB) nu-
clear translocation and inhibition of proinflammatory-
cytokine-induced RA-FLS proliferation [18]. PRG4 from
RA SF binds L-selectin and coats the surface of poly-
morphonuclear cells (PMNs) [19, 20].
Given the emerging evidence of a biological role for
PRG4, we hypothesized that PRG4 acts as an endogen-
ous anti-inflammatory agent in SF through its ability to
interact with multiple receptor families. The objective of
this investigation was to evaluate the ability of rhPRG4
and native human PRG4 (nhPRG4) to bind to toll-like
receptors 2 and 4 (TLR2 and TLR4) and whether this
interaction will provide an anti-inflammatory effect by
preventing TLR2 and TLR4 activation by agonists and
by ligands in SF from patients with OA and RA.
Methods
Binding of recombinant and native human PRG4 to TLR2
and TLR4 using a direct enzyme-linked immunosorbent
assay (ELISA) approach
High-binding microtiter plates (Corning, Sigma Aldrich,
St. Louis, MO, USA) were used to coat recombinant hu-
man TLR2 or TLR4 overnight at 4 °C (R&D Systems,
Minneapolis, MN, USA). Each well received 100 μL of
TLR2 or TLR4 (1 μg/mL each) in phosphate-buffered sa-
line (PBS). Wells that were coated with TLR2 or TLR4 or
corresponding uncoated control wells were blocked with
2 % bovine serum albumin (BSA; 300 μL per well) for 2 h
at room temperature. rhPRG4 or nhPRG4 were added at
50, 10, 1, and 0.1 μg/mL (100 μL per well) and incubated
for 1 h at room temperature. rhPRG4 is a full-length prod-
uct produced by CHO-M cells (Lubris, Framingham, MA,
USA) [21]. nhPRG4 is purified from culture supernatants
of human FLS as previously described [13]. rhPRG4 and
nhPRG4 have similar immunoreactivity towards anti-
PRG4 antibodies and have similar molecular weights
assessed by gel electrophoresis [21]. Following washing with
PBS + 0.05 % tween 20, anti-PRG4 antibody (9G3, EMD
Millipore, Billerica, MA, USA) [22] was added at 1:1,000 di-
lution in PBS + 0.05 % tween 20 with each well receiving
100 μL of the antibody solution and incubated for 1 h at
room temperature. Wells were washed with PBS + 0.05 %
tween 20 and sheep anti-mouse IgG-horseradish peroxidase
(HRP) was added (1:5,000 dilution; 100 μL per well) and in-
cubated at room temperature for 1 h. Following washing
with PBS + 0.05 % tween 20, the assay was developed using
1-step Turbo TMB ELISA reagent (ThermoFisher Scientific,
Waltham, MA, USA) and the absorbance was measured at
450 nm. Data are presented as fold-change in the 450 nm
absorbance values above uncoated wells (non-specific bind-
ing). Data represent the mean ± SD of four independent
experiments with at least triplicate wells per group.
Association of fluorescently labeled rhPRG4 with TLR2- and
TLR4-expressing human embryonic kidney (HEK) cells using
flow cytometry
rhPRG4 was labeled with Rhodamine using a commercially
available labeling kit according to the manufacturer’s
recommendation (Pierce NHS–Rhodamine Antibody La-
beling Kit, ThermoFisher Scientific). Association of rhPRG4
with TLR2 and TLR4 was studied following incubation of
Rhodamine-rhPRG4 with HEK-Blue hTLR2 and HEK-Blue
hTLR4 cells (Invivogen, San Diego, CA, USA). TLR2-HEK
and TLR4-HEK cells are genetically engineered reporter
cells derived from HEK cells by co-transfection of the hu-
man TLR2 with an inducible secreted embryonic alkaline
phosphatase (SEAP) or the co-transfection of the human
TLR4, MD-2 and CD14 co-receptor genes with the SEAP
reporter gene. Activation of TLR2 or TLR4 results in nu-
clear translocation of NFκB and expression of SEAP, whose
activity can be detected in the culture media.
A total of 100,000 TLR2-HEK or TLR4-HEK cells were
plated per well in sterile tissue culture plates. Cells were
treated with Rhodamine-rhPRG4 (20 μg/mL) for 12 or 24 h.
Following incubation, cells were harvested using cell
scrapers, pelleted and washed with PBS. Cell associated
fluorescence was analyzed using Guava easyCyte Flow Cyt-
ometer (EMD Millipore). Cell-associated fluorescence was
measured across independent experiments using the same
acquisition parameters. A threshold was set at red fluores-
cence intensity = 10, and cells that displayed fluorescence in-
tensity higher than the threshold were counted as positively
associating with Rhodamine rhPRG4. Data are presented as
percentage positive cells across different treatments. Data
represent the mean ± SD of four independent experiments.
Inhibition of TLR2 and TLR4 activation by nhPRG4
In sterile 96-well plates (Corning, Sigma Aldrich), 25,000
cells of either TLR2-HEK or TLR4- HEK cells were plated
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per well. Cells were suspended in HEK Blue detection
media (Invivogen) and the total volume in each well was
200 μL. HEK Blue detection media contains a SEAP
substrate that allows the colorimetric detection of SEAP
activity. TLR2-HEK cells were treated with a TLR2 agon-
ist, Pam3CSK4 (Invivogen) (50 ng/mL) in the absence or
presence of nhPRG4 (50, 100, and 150 μg/mL) and cells
were incubated at 37 °C for 24 h. Pam3CSK4 was diluted
in endotoxin-free water and subsequently added to the
cells in HEK detection media. The 630 nm absorbance
was measured and normalized to untreated control cells.
Data are presented as fold-change in 630 nm above
untreated control cells. Data represent the mean ± SD of
four independent experiments with at least duplicate wells
per experimental group. TLR4-HEK cells were treated
with 50 ng/mL lipopolysaccharide (LPS; Invivogen) in the
absence or presence of nhPRG4 (50, 100 and 150 μg/mL)
and cells were incubated at 37 °C for 20 h. LPS was diluted
in endotoxin-free water and subsequently added to the
cells in HEK detection media. The 630 nm absorbance
was measured and normalized to untreated control cells.
Data are presented as fold-change in 630 nm above
untreated control cells. Data represent the mean ± SD of
four independent experiments with at least duplicate wells
per experimental group.
Activation of TLR2 and TLR4 by OA and RA SF and the
effect of nhPRG4 treatment
Samples from RA (n = 10), OA (n = 8) and normal (n = 3)
SF specimens were used throughout this study. SF aliquots
from five RA patients were kindly provided by Dr. Stefan
Lohmander. These samples were collected with patients’
consent and approved by the central ethical review board
at Lund University, Lund, Sweden. The remainder of the
SF specimens were acquired from Articular Engineer-
ing, Northbrook, IL, USA, following knee replacement
surgery or from donors within 24 h of death, collected
with partner site Institutional Review Board (IRB) ap-
proval with informed written consent from the donor or
nearest relative. This study was approved by the IRB at
the Massachusetts College of Pharmacy and Health Sci-
ences. Nine of the RA patients were female. The median
age (interquartile range) of the group was 73 (57 to 75)
years. Eight patients were on a methotrexate regimen,
among whom four patients were on combined treatment
with a disease-modifying biologic agent. Five of the OA
patients were female. The median age (interquartile range)
of the group was 65 (59 to 69) years. Normal SF speci-
mens were obtained from subjects with no clinical history
of joint disease or arthritis. Two normal subjects were
male (56 and 62 years old) and one was female (35 years
old). OA, RA and normal SF specimens (7.5 μL per well;
3.75 % SF dilution) were incubated with TLR2-HEK cells
(25,000 cells per well in HEK Blue detection media). The
final volume in each well was 200 μL. Cells were incu-
bated with the SF samples for 48 h at 37 °C. The 630 nm
absorbance was measured and normalized to the 630 nm
absorbance values of untreated control cells. A similar ap-
proach was adopted for measuring the activation of
TLR4-HEK cells with OA, RA and normal SF.
In a separate set of experiments, OA SF samples (n = 8)
or RA SF samples (n = 5) (7.5 μL per well; 3.75 % SF dilu-
tion) were incubated with TLR2-HEK cells (25,000 cells
per well in HEK Blue detection media) in the absence or
presence of nhPRG4 (100 μg/mL). The final volume in
each well was 200 μL. Cells were incubated with the SF
samples for 48 h at 37 °C. The 630 nm absorbance was
measured and normalized to the 630 nm absorbance
values of untreated control cells. Similarly, OA SF samples
(n = 8) or RA SF samples (n = 5) (7.5 μL per well; 3.75 %
SF dilution) were incubated with TLR4-HEK cells (25,000
cells per well in HEK Blue detection media) in the absence
or presence of nhPRG4 (150 μg/mL). The final volume in
each well was 200 μL. Cells were incubated with the SF
samples for 48 h at 37 °C. The 630 nm absorbance was
measured and normalized to 630 nm absorbance values of
untreated control cells.
Immunoprecipitation of PRG4 from OA and RA SF
SF aliquots from OA patients (n = 5) and RA patients
(n = 5) were pooled and digested with Streptomyces
hylauronidase (Sigma Aldrich) at a final enzyme con-
centration of 3 units/ml for 3 h at 37 °C. Digested
pooled OA and pooled RA SF underwent two rounds
of PRG4 depletion by immunoprecipitation. In each
round, SF aliquots were incubated with monoclonal
anti-PRG4 antibody, 9G3 (1:100 dilution) for 2 h at 37 °
C. Subsequently, G-protein-coupled Dynabeads (Ther-
moFisher Scientific) were added to the OA and RA SF
(1.5 mg) and incubated at 37 °C for 1 h followed by
magnetic separation (DynaMag, ThermoFisher Scien-
tific). Fresh magnetic beads were added (1.5 mg) and
magnetic separation was conducted as described above.
To confirm PRG4 depletion from OA and RA SF, SF
aliquots were assayed for PRG4 content using a PRG4
inhibition ELISA as previously described [23].
Effect of PRG4 removal on TLR2 and TLR4 activation by
OA and RA SF
PRG4-immunoprecipitated pooled OA or RA SF and
pooled OA or RA SF, at 1.0, 7.5, 10.0 and 20.0 μL, were in-
cubated with TLR2-HEK cells (25,000 cells per well in
HEK Blue detection media) for 24 h at 37 °C. The final
volume in each well was 200 μL, corresponding to SF
dilution of 0.5, 3.75, 5.0 and 10.0 %. The 630 nm absorb-
ance was measured and normalized to untreated control
cells. Similarly, PRG4-immunoprecipitated pooled OA or
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RA SF and pooled OA or RA SF were incubated with
TLR4-HEK cells as described above.
In a separate set of experiments, PRG4-immunoprecipitated
pooled OA or RA SF and pooled OA or RA SF at 5 % SF
dilution were incubated with TLR2-HEK cells (25,000
cells per well in HEK Blue detection media) in the ab-
sence or presence of nhPRG4 (100, 200 and 300 μg/mL)
for 24 h at 37 °C, followed by absorbance measurement
as described above.
Statistical analyses
Variables were initially tested for normality and equal
variances. Variables that satisfied both assumptions were
tested for statistical significance using Student’s t test or
analysis of variance (ANOVA) with Tukey’s post-hoc test
for two-group and more than two-group comparisons,
respectively. Variables that did not satisfy the normality
assumption were tested using the Mann–Whitney U test
or ANOVA on the ranks. The level of statistical signifi-
cance was set at α = 0.05. Data are presented as the
mean ± SD. Unless otherwise specified, data represent
the mean of three independent experiments with dupli-
cate wells per experimental group.
Results
Binding of rhPRG4 and nhPRG4 to immobilized TLR2 and
TLR4
The concentration-dependent binding of rhPRG4 and
nhPRG4 to TLR2 is shown in Fig. 1a. rhPRG4 and nhPRG4
concentrations are reported in μg/Ml and PRG4 in pmoles,
based on a predicted molecular weight of 240 kDa [18].
rhPRG4 (1, 10, and 50 μg/mL), corresponding to 0.4, 4 and
21 pmoles, significantly binds to TLR2-coated wells (1.5
pmoles per well based on a predicted molecular weight of
66 kDa) compared to uncoated wells (p <0.001). nhPRG4
(10 and 50 μg/mL), corresponding to 4 and 21 pmoles,
significantly binds to TLR2-coated wells compared to
uncoated wells (p <0.001). There was concentration-
dependent binding of rhPRG4 to TLR2, with significant
reduction in binding to TLR2 at 1 μg/mL compared to the
10 and 50 μg/mL (p <0.001). Similarly, rhPRG4 (10 μg/mL)
displayed significant reduction in binding to TLR2 com-
pared to rhPRG4 (50 μg/mL). nhPRG4 displayed a reduc-
tion in TLR2 binding at 10 μg/mL compared to 50 μg/mL.
rhPRG4 demonstrated significantly higher binding to TLR2
compared to nhPRG4 at 1 and 10 μg/mL (p <0.001).
rhPRG4 (10 and 50 μg/mL), corresponding to 4 and 21
pmoles, significantly binds to TLR4-oated wells (1.4 pmoles
per well based on a predicted molecular weight of 70 kDa)
compared to uncoated wells (p <0.001) (Fig. 1b). nhPRG4
(10 and 50 μg/mL), corresponding to 4 and 21 pmoles,
significantly binds to TLR4 coated wells compared to
uncoated wells (p <0.001). Both rhPRG4 and nhPRG4
displayed concentration-dependent binding to TLR4 as the
50 μg/mL in both forms of the protein significantly binds
to TLR4 compared to 10 μg/mL (p <0.001).
Association of rhPRG4 with TLR2-HEK and TLR4-HEK cells
Representative flow cytometry scatter plots showing time-
dependent association of fluorescently labeled rhPRG4
withTLR2-HEK and TLR4-HEK cells are shown in Fig. 2a.
Control untreated cell population is located in the lower
left quadrant of the graph. Treatment of TLR2-HEK cells
with rhPRG4 for 12 and 24 h resulted in a cell population
Fig. 1 Binding of recombinant human proteoglycan-4 (rhPRG4) and native human PRG4 (nhPRG4) to recombinant toll-like receptors 2 and 4 (TLR2
and TLR4) using a direct binding enzyme linked immunosorbent assay. PRG4 concentrations are reported in μg/mL and pmoles per well, based
on a predicted molecular weight of 240 kDa. TLR2 and TLR4 are expressed as pmoles coated per well, based on predicted molecular weights of
66 and 70 kDa, respectively. The 450 nm absorbance values were normalized to non-specific binding. Data represent the mean ± SD from four
independent experiments. Dashed line represents non-specific binding (background). a Concentration-dependent binding of rhPRG4 and nhPRG4
to immobilized TLR2. rhPRG4 exhibited a concentration-dependent binding at 50, 10 and 1 μg/mL. nhPRG4 exhibited a concentration-dependent
binding at 50 and 10 μg/mL; *p <0.001. b Concentration-dependent binding of rhPRG4 and nhPRG4 to immobilized TLR4. rhPRG4 and nhPRG4
exhibited concentration-dependent binding at 50 and 10 μg/mL; *p <0.001
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shift to the lower right quadrant indicating that rhPRG4
was associated with TLR2-HEK cells. Similarly, treatment
of TLR4-HEK cells with rhPRG4 for 12 and 24 h exhibited
a similar shift indicating that rhPRG4 was associated with
TLR4-HEK cells.
Quantitative analysis of rhPRG4 association with TLR2-
HEK and TLR4-HEK cells is shown in Fig. 2b. At 12 and
24 h, the percentage of TLR2-HEK and TLR4-HEK cells
that were associated with rhPRG4 was significantly higher
than control (p <0.001). For TLR2-HEK, the percentage of
cells that associated with rhPRG4 following incubation for
24 h was significantly higher than the corresponding
percentage following incubation for 12 h (p = 0.011). Simi-
larly, percentage of TLR4-HEK cells that associated with
rhPRG4 following incubation for 24 h was significantly
higher than the corresponding percentage following
Fig. 2 Association of recombinant human proteoglycan-4 (rhPRG4) with toll-like receptor-2 and 4 (TLR2 and TLR4) expressing human embryonic
kidney (TLR2-HEK and TLR4-HEK) cells. Data represent the mean ± SD from four independent experiments. a Representative flow cytometry scatter plots
of rhodamine-labeled rhPRG4 (20 μg/mL) association with TLR2-HEK and TLR4-HEK cells following incubation for 12 and 24 h. A threshold was set at
red fluorescence intensity = 10. Cell-associated fluorescence higher than 10 was considered positive. Following incubation of rhodamine-rhPRG4 with
TLR2-HEK and TLR4-HEK cells for 12 or 24 h, cell association was observed. b Quantitative analysis of the percentage of positive TLR2-HEK and
TLR4-HEK cells following incubation with rhodamine-rhPRG4 (20 μg/mL) for 12 and 24 h. rhPRG4 was significantly associated with TLR2-HEK and
TLR4-HEK at 24 h compared to 12 h and controls. The 12-h association between rhPRG4 and TLR2-HEK cells was significantly higher than with
TLR4-HEK cells and both were higher than control; *p <0.001, ** p <0.05
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incubation for 12 h (p <0.001). Following incubation for
12 h, rhPRG4 showed significantly higher association with
TLR2-HEK compared to TLR4-HEK cells (p <0.001). In
contrast, there was no significant difference in rhPRG4
association with TLR2-HEK and TLR4-HEK cells follow-
ing 24-h treatment (p = 0.353).
nhPRG4 blocks agonist-induced activation of TLR2 and
TLR4
The effect of nhPRG4 treatment on agonist-induced
TLR2 activation is shown in Fig. 3a. Pam3CSK4 treat-
ment resulted in significant TLR2 activation compared
to control (p <0.001). Co-incubation of nhPRG4 (50,
100 and 150 μg/mL) with Pam3CSK4 significantly re-
duced TLR2 activation compared to Pam3CSK4 only
treatment (p <0.001). nhPRG4 (100 and 150 μg/mL)
treatment was more efficacious in reducing TLR2 acti-
vation than nhPRG4 (50 μg/mL) (p <0.001, p <0.001).
nhPRG4 (150 μg/mL) and nhPRG4 (100 μg/mL) treat-
ments were equally efficacious in reducing TLR2 activa-
tion (p = 0.718). nhPRG4 (150 μg/mL) alone did not
stimulate TLR2 receptor compared to untreated control
cells.
The effect of nhPRG4 treatment on agonist-induced
TLR4 activation is shown in Fig. 3b. LPS treatment re-
sulted in significant TLR4 activation compared to un-
treated control cells (p <0.001). Co-incubation of
nhPRG4 (50, 100 and 150 μg/mL) with LPS resulted in a
significant reduction in TLR4 activation compared to
LPS only treatment (p = 0.033, p <0.001, p <0.001).
nhPRG4 (100 and 150 μg/mL) treatment was more effi-
cacious in reducing TLR4 activation than nhPRG4
(50 μg/mL) (p = 0.003, p <0.001). Similarly, nhPRG4
(150 μg/mL) treatment was more efficacious in
reducing TLR4 activation than nhPRG4 (100 μg/mL)
(p <0.001). nhPRG4 (150 μg/mL) alone did not stimu-
late TLR4 receptor compared to untreated control
cells.
OA and RA SF activate TLR2 and TLR4 and nhPRG4
treatment blocks SF-mediated activation
Activation of TLR2 and TLR4 by OA SF and RA SF
samples is shown in Fig. 4a. Normal SF did not result in
TLR2 or TLR4 activation compared to control. RA SF
treatment resulted in significantly higher TLR2 activa-
tion compared to OA SF and normal SF (p <0.001).
Similarly, OA SF treatment resulted in a significantly
higher TLR2 activation compared to normal SF (p
<0.001). Both OA and RA SF significantly activated
TLR4 compared to normal SF and control (p <0.001).
There was no significant difference in TLR4 activation
between OA SF and RA SF (p = 0.786). nhPRG4
(100 μg/mL) treatment significantly reduced TLR2 acti-
vation by Pam3CSK4, OA SF and RA SF (p <0.001)
(Fig. 4b). Similarly, rhPRG4 (150 μg/mL) treatment
significantly reduced TLR4 activation by LPS, OA SF
and RA SF (p <0.001) (Fig. 4c).
Fig. 3 Concentration-dependent effect of native human proteoglycan 4 (nhPRG4) on agonist-induced activation of toll-like receptors 2 and 4 (TLR2 and
TLR4) expressing human embryonic kidney (TLR2-HEK and TLR4-HEK) cells. Absorbance values across groups were normalized to untreated cells (control).
Data represents the mean ± SD from four independent experiments. a Inhibition of Pam3CSK4-induced activation of TLR2 by nhPRG4 treatment.
Pam3CSK4 significantly activated TLR2. nhPRG4 (50, 100 and 150 μg/mL) co-incubation significantly reduced Pam3CSK4-induced TLR2 activation. nhPRG4
(100 and 150 μg/mL) treatments were more efficacious in reducing TLR2 activation than nhPRG4 (50 μg/mL). nhPRG4 alone did not stimulate TLR2;
*p <0.001. b Inhibition of lipopolysaccharide (LPS)-induced activation of TLR4 by nhPRG4 treatment. LPS significantly activated TLR4. nhPRG4 (50, 100 and
150 μg/mL) co-incubation significantly reduced LPS-induced TLR4 activation. nhPRG4 (100 and 150 μg/mL) treatments were more efficacious in reducing
TLR4 activation than nhPRG4 (50 μg/mL). nhPRG4 (150 μg/mL) treatment was more efficacious in reducing TLR4 activation than nhPRG4 (100 μg/mL).
nhPRG4 alone did not stimulate TLR4; *p <0.001, **p <0.01, ***p <0.05
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Effect of PRG4 depletion by immunoprecipitation on OA
and RA SF-mediated activation of TLR2 and TLR4
PRG4 depletion from pooled OA and RA SF was con-
firmed using PRG4 ELISA. The mean PRG4 concentra-
tion in OA SF was 280.43 ± 14.76 μg/mL compared to
25.11 ± 3.18 μg/mL in PRG4-depleted OA SF (OA SF
(-PRG4)). The mean PRG4 concentration in RA SF was
226 ± 4.09 μg/mL compared to 32.17 ± 5.57 μg/mL in
PRG4-depleted RA SF (RA SF (-PRG4)). The effect of
PRG4 depletion on TLR2 activation by OA SF is shown
in Fig. 5a. There was no significant difference in TLR2
activation between OA SF and OA SF (-PRG4) at 0.5 %
SF dilution. At 3.75, 5 and 10 % SF dilution, OA SF
(-PRG4) treatment resulted in significantly higher TLR2
activation compared to OA SF treatment and untreated
controls (p <0.001). Similarly, at 3.75, 5 and 10 % SF di-
lution, OA SF treatment resulted in significantly higher
TLR2 activation compared to untreated control cells
(p <0.001). The effect of PRG4 depletion on TLR2 ac-
tivation by RA SF is shown in Fig. 5b. There was no
significant difference in TLR2 activation between RA
SF and RA SF (-PRG4) at 0.5 and 3.75 % SF dilution.
At 5 and 10 % SF dilution, RA SF (-PRG4) treatment
resulted in increased TLR2 activation compared to
RA SF treatment (p <0.001). Similarly, at 3.75, 5 and
10 % SF dilution, RA SF treatment resulted in signifi-
cantly higher TLR2 activation compared to untreated
control cells (p <0.001).
The effect of PRG4 depletion on TLR4 activation by
OA and RA SF is shown in Fig. 5c. At 0.5, 3.75, 5.0 and
10.0 % SF dilution, OA SF and OA SF (-PRG4) treat-
ments resulted in significantly higher TLR4 activation
compared to untreated controls (p <0.001). There was
no significant difference in TLR4 activation between OA
Fig. 4 Activation of toll-like receptors 2 and 4 (TLR2 and TLR4) expressing human embryonic kidney (TLR2-HEK and TLR4-HEK) cells by synovial fluids
(SF) from subjects with no joint arthropathy (normal; n = 3), patients with osteoarthritis (OA; n = 8) and patients with rheumatoid arthritis (RA; n = 5) and
effect of native human proteoglycan-4 (nhPRG4) treatment. SF samples were incubated with TLR2- or TLR4-HEK cells (3.75 % dilution) at 37 °C for 48 h.
Absorbance values across groups were normalized to untreated cells (control). Data represent the mean SD from three independent experiments.
a Activation of TLR2 and TLR4 by normal, OA and RA SF. Normal SF did not significantly activate TLR2 or TLR4 compared to control. OA SF and RA SF
significantly activated TLR2 and TLR4 compared to normal SF and control. RA SF significantly activated TLR2 compared to OA SF; *p <0.001. b Impact
of nhPRG4 treatment (100 μg/mL) on Pam3CSK4, OA SF and RA SF-induced activation of TLR2. nhPRG4 treatment inhibited Pam3CSK4, OA SF and RA
SF-induced TLR2 activation; *p <0.001. c Impact of nhPRG4 treatment (150 μg/mL) on lipopolysaccharide (LPS), OA SF and RA SF-induced activation of
TLR4. nhPRG4 treatment inhibited LPS, OA SF and RA SF-induced TLR4 activation; *p <0.001
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SF and OA SF (-PRG4) across the various SF dilutions.
RA SF and RA SF (-PRG4) significantly activated TLR4
compared to untreated controls at all the SF dilutions
(p <0.001). PRG4 depletion from pooled RA SF did not
result in a significant change in TLR4 activation com-
pared to non-depleted RA SF across all SF dilutions.
The impact of nhPRG4 supplementation on TLR2
activation by PRG4-depleted OA SF is shown in Fig. 6a.
OA SF treatment resulted in significantly higher TLR2
activation compared to untreated controls (p <0.001).
Likewise, OA SF (-PRG4) treatment resulted in signifi-
cantly higher TLR2 activation compared to OA SF and
untreated controls (p <0.001). There was no significant
difference between TLR2 activation in the OA SF
(-PRG4) and OA SF (-PRG4) + nhPRG4 (100 μg/mL)
groups (p = 0.454). TLR2 activation was significantly re-
duced in the OA SF (-PRG4) + nhPRG4 (200 or 300 μg/
mL) compared to OA SF (-PRG4) (p <0.001). There was
no significant difference in TLR2 activation between OA
SF (-PRG4) + nhPRG4 (300 μg/mL) and OA SF (-PRG4)
+ nhPRG4 (200 μg/mL) (p = 0.312). There was a trend
towards a significant reduction in TLR2 activation of
OA SF (-PRG4) + nhPRG4 (200 μg/mL) and OA SF
(-PRG4) + nhPRG4 (100 μg/mL) (p = 0.051).
The impact of nhPRG4 supplementation on TLR2
activation by PRG4-depleted RA SF is shown in Fig. 6b.
RA SF treatment resulted in a significant activation of
TLR2 compared to untreated controls (p = 0.003). RA SF
(-PRG4) treatment significantly activated TLR2 com-
pared to RA SF and untreated controls (p <0.001). There
was no significant difference in TLR2 activation between
RA SF (-PRG4) and RA SF (-PRG4) + nhPRG4 (100 μg/
mL) (p = 0.155). TLR2 activation was significantly re-
duced in RA SF (-PRG4) + nhPRG4 (200 or 300 μg/mL)
compared to RA SF (-PRG4) (p <0.001). Similarly, TLR2
activation in RA SF (-PRG4) + nhPRG4 (200 or 300 μg/
mL) was significantly reduced compared to RA SF
(-PRG4) + nhPRG4 (100 μg/mL) (p = 0.004; p <0.001).
Fig. 5 Impact of proteoglycan-4 (PRG4) immunoprecipitation on activation of toll-like receptors 2 and 4 (TLR2 and TLR4) expressing human embryonic
kidney (TLR2-HEK and TLR4-HEK) cells by pooled osteoarthritis (OA) (n = 5) and pooled rheumatoid arthritis (RA) (n = 5) synovial fluid (SF). OA or RA SF with
or without PRG4 immunoprecipitation were incubated with TLR2-HEK or TLR4-HEK cells (0.5, 3.75, 5.0 and 10.0 % dilution) at 37 °C for 24 h. The 630 nm
absorbance values across experimental groups were normalized to untreated controls. Data represent the mean ± SD from three independent experiments.
a Impact of PRG4 immunoprecipitation on TLR2 activation by OA SF. TLR2 activation was significantly higher in PRG4-immunoprecipitated OA SF (OA SF
(-PRG4)) compared to OA SF at 3.75, 5.0 and 10.0 %; *p <0.001. b Impact of PRG4 immunoprecipitation on TLR2 activation by RA SF. TLR2 activation was
significantly higher in PRG4 immunoprecipitated RA SF (RA SF (-PRG4)) compared to RA SF at 5 and 10 %; *p <0.001. c Impact of PRG4
immunoprecipitation on TLR4 activation by OA SF and RA SF. There was no significant difference in TLR4 activation between OA SF and
OA SF following PRG4 immunoprecipitation (OA SF (-PRG4)) across any SF dilutions. There was no significant difference in TLR4 activation
between RA SF and RA SF following PRG4 immunoprecipitation (RA SF (-PRG4)) across any SF dilutions
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There was no significant difference in TLR2 activation
between RA SF (-PRG4) + nhPRG4 (200 μg/mL) and RA
SF (-PRG4) + nhPRG4 (300 μg/mL) (p = 0.672).
Discussion
The TLR family is a large family of receptors, with at least
11 members that have been identified thus far [24]. The
TLRs play an important role in the host defense mechan-
ism as part of the innate immune response. The different
members of the TLR family have evolved to recognize
pathogen-associated molecular patterns (PAMPs), including
cell wall components of Gram-positive, Gram-negative
bacteria, viruses and fungi [24]. TLRs are also stimulated by
damage-associated molecular patterns (DAMPs). DAMPs
are host-derived proteins including extracellular matrix
components, and macromolecule fragments that are re-
leased due to tissue injury and cell death and can activate
the TLRs [25]. Examples of DAMPs that were shown to
activate TLRs, specifically TLR2 or TLR4, in the joint envir-
onment include biglycan, high mobility group box 1 protein
(HMGB1), glycoprotein 96 (gp96), fibronectin, low molecu-
lar weight hyaluronan fragments, and an aggrecan fragment
among others [26–32]. Binding of DAMPs to TLR2 or
TLR4 activates signaling pathways that are myeloid differ-
entiation primary response gene 88 (MyD88)-dependent or
MyD88-independent [33]. The downstream effects include
activation of MAPK, PI3K and NFκB [33, 34] with the ex-
pression of proinflammatory cytokines and mediators e.g.,
inducible nitric oxide synthase (iNOS) and cyclooxygenase
2 (COX-2) [35, 36]. A role for innate immune response
and TLR activation is suggested in the pathogenesis of
OA [33, 37]. Chondrocytes derived from a TLR2/TLR4
double knockout mouse resisted the pro-catabolic effect
of low molecular weight hyaluronan fragments and
showed attenuated matrix metalloproteinase-13 (MMP-
13) expression [38]. In RA, blocking TLR2 inhibits the
spontaneous release of cytokines from synovial explant
cultures [39]. Furthermore, TLR2 and TLR4 can act syner-
gistically to upregulate inflammatory cytokine production
from human RA synovial fibroblasts [40, 41].
Given the importance of TLR2 and TLR4 activation and
signaling in OA and RA pathogenesis, we aimed to study
whether PRG4 can interact with TLR2 and TLR4 and the
functional consequence of this interaction. In this work, we
present data supporting that PRG4, in its native and recom-
binant forms, can bind to immobilized TLR-2 and TLR-4.
PRG4 exhibited concentration-dependent binding to TLR2
and TLR4. Furthermore, PRG4 might have exhibited a
greater affinity towards binding TLR2 compared to TLR4,
especially at the higher PRG4 concentrations evaluated.
Using fluorescently labeled PRG, we have demonstrated
that PRG4 can associate with cells that overexpress TLR2
and TLR4. In the cell association studies, PRG4 displayed
better association with TLR2 expressing cells at the earlier
time point examined. The binding of PRG4 to TLR2 and
TLR4 may explain the concentration-dependent antagon-
ism of TLR2 and TLR4 activation by bacterial cell wall
ligands of the latter. The upstream effects of PRG4 in the
Fig. 6 Impact of native human proteoglycan-4 (nhPRG4) treatment (100, 200 and 300 μg/mL) on toll-like receptor 2 (TLR2) activation by pooled
osteoarthritis (OA) synovial fluid (SF) and pooled rheumatoid arthritis (RA) SF following proteoglycan-4 (PRG4) immunoprecipitation. TLR2-expressing
human embryonic kidney (TLR2-HEK) cells were incubated with SF (5 % dilution for 24 h) in the absence or presence of nhPRG4. The 630 nm
absorbance values across experimental groups were normalized to untreated controls. Data represent the mean ± SD from three independent
experiments. a Impact of nhPRG4 on TLR2 activation of PRG4-immunoprecipitated OA SF (OA SF (-PRG4)). nhPRG4 treatments (200, 300 μg/mL)
significantly reduced TLR2 activation by OA SF (-PRG4). nhPRG4 (300 μg/mL) treatment was more efficacious in reducing TLR2 activation than nhPRG4
(100 μg/mL); *p <0.001; **p <0.05. b Impact of nhPRG4 on TLR2 activation of PRG4-immunoprecipitated RA SF (RA SF (-PRG4)). nhPRG4 treatments
(200, 300 μg/mL) significantly reduced TLR2 activation by RA SF (-PRG4). nhPRG4 (200 and 300 μg/mL) treatment was more efficacious in reducing
TLR2 activation than nhPRG4 (100 μg/mlL); *p <0.001; **p <0.01
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TLR2 and TLR4 signaling cascade, namely blocking access
to the TLR receptor, translated to inhibition of NFκB
nuclear translocation. PRG4 alone did not alter the back-
ground level activation of TLR2 and TLR4 with no detect-
able receptor activation following incubation of the cells
with PRG4 above that of background. Towards this end,
PRG4 acts as a pure antagonist on the TLR2 and TLR4.
We observed that RA SF activated TLR2 and TLR4 to
a greater extent compared to SF from subjects without
history of joint arthropathy. We also report that the RA
SF that we examined activates TLR2 to a greater extent
compared to OA SF. These findings are in an agreement
with previous studies in which RA SF activates TLR2-
HEK and TLR4-HEK cells [42]. In our study, the magni-
tude of activation by RA SF was considerably lower than
previously reported [42], which could be attributed to
the significantly lower SF dilution used in our study. We
also observed that OA SF activated TLR2 and TLR4.
Previous reports have demonstrated that SF from pa-
tients with early OA augments the TLR ligand-mediated
stimulation of FLS [43] and that plasma proteins present
in OA SF stimulate cytokine production in a TLR4-
dependent manner [44]. In our study, PRG4 was effica-
cious in blocking RA SF and OA SF induced TLR2 and
TLR4 activation, with a lower PRG4 concentration re-
quired to block TLR2 compared to TLR4. Removing
PRG4 from SF dramatically increased TLR2 activation
by OA SF and RA SF. Additionally, PRG4 at a previously
efficacious concentration that blocked TLR2-induced
activation by OA SF and RA SF, had significantly re-
duced efficacy when used in OA SF and RA SF where
PRG4 had been depleted. A higher PRG4 concentration
was needed to block the excessive TLR2 stimulation of
PRG4-immunoprecipitated OA SF and RA SF. By con-
trast, PRG4 removal from OA SF and RA SF had no
effect on TLR4 activation, as PRG4-depeleted and con-
trol OA and RA SF demonstrated a similar pattern of
TLR4 activation. This observed specificity of SF PRG4
towards TLR2 vs. TLR4 antagonism might be explained
by the presence of higher fluid concentrations of TLR2
ligands than TLR4 ligands in the specimens we have
studied. Additionally, preferential binding of PRG4 to
TLR2 compared to TLR4 may also contribute to this
observed specificity.
PRG4’s protein core is 1,404 amino acids long with N
and C terminals and a central mucin domain [9]. The cen-
tral mucin domain is heavily glycosylated via O-linked
β(1-3)Gal-GalNAc oligosaccharides, and is configured to
form a nanofilm that exerts repulsive forces, and provides
the basis for its anti-adhesive and lubricating properties
[45]. Removal of central domain glycosylation results in a
loss of the boundary lubricating ability of PRG4 [46]. The
nature of PRG4 glycosylation pattern may influence a bio-
logical role for PRG4 as altered glycosylation in PRG4
isolated from RA SF forms a ligand for L-selectin [19, 20,
47]. However, PRG4 binding to CD44 is not dependent on
PRG4 glycosylation [18]. PRG4 amino terminal domains
are homologous to the somatomedin B domain of vitro-
nectin and the carboxy terminal contains a hemopexin
domain [9] and may mediate surface binding of the pro-
tein [48]. The N and C terminals may allow PRG4 to sim-
ultaneously interact with multiple receptor families and
modulate the downstream signaling of its binding part-
ners. Unique to PRG4 is its ability to block NFκB activa-
tion downstream from two distinctly different receptor
families, namely CD44 and the TLRs.
Conclusions
In summary, we present data suggesting that PRG4
binds to TLR2 and TLR4 and associates with cells that
overexpress these two receptors. In this interaction,
PRG4 acts as an antagonist to prevent TLR2 and TLR4
activation by bacterial ligands and by a ligand present in
SF from patients with inflammatory arthritis. An en-
dogenous anti-inflammatory role for PRG4 is further
characterized by increased TLR2 activation by OA and
RA SF upon PRG4 removal and reversal of this effect
following re-introduction of PRG4. This work, along
with recent published reports [18, 20], identified a bio-
logical role for PRG4 that may be important to the onset
and progression of chronic inflammatory joint diseases and
provides a rationale for PRG4 as an anti-inflammatory
agent.
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